DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1575)

TreatmentTrends: Multiple Sclerosis (EU) 2013

BioTrends Research Group is pleased to announce the continuation of TreatmentTrends®: Multiple Sclerosis in the EU report in 2013.
TreatmentTrends® are syndicated report series that provide longitudinal information on market dynamics. They provide insight into practice patterns, attitudes and perceptions, and current and projected use of various products.
TreatmentTrends® evaluate perceived product advantages and disadvantages, as well as sales and messaging efforts of key market players.

Questions Answered in This Report:

  • Compare perceptions and differences in the management and treatment of MS patients across the EU5 regions (France, Germany, Spain, Italy, and the UK)

  • Understand the relative MS patient load by disease classification (CIS, RRMS, PRMS, SPMS, and PPMS) and how DMAs are used in each group

  • Understand product attributes that are most important to neurologists when selecting DMAs and compare the different brands on how they are perceived to perform against each attribute

  • Understand how the use of each DMA brand is expected to change in the next six months and what factors are driving those trends

  • Evaluate sales strategies and messaging efforts of DMA therapies

  • Assess awareness of and interest in DMA therapies that are in late stage development


Sample Frame & Methodology:

- ~225 neurologists are complete a 45-minute online quantitative survey with several open-ended questions for quali-tative feedback

To qualify, respondents must meet the following criteria:

- Minimum of 20 patients with relaps-ing remitting multiple sclerosis (RR-MS) under management

- Have been in practice a minimum of 2 years and a maximum of 35 years

- More than 75% of professional time spent in clinical practice

The neurologists are recruited from the France (n=50), Germany (n=50), Italy (n=50), Spain (n=48), and UK (n=28)


- Final report in powerpoint format

- Complete set of frequency tables, summary statistics, and cross tabulations, including analysis between EU regions, can be provided upon request

- Proprietary question slide deck

- Clients purchasing prior to fielding will have the opportunity to include up to three proprietary questions

Product Coverage:

- Approved: Aubagio, Avonex, Betaferon, Copaxone, Extavia, Gilenya, Lemtrada, Rebif, Tecfidera, Tysabri

- In development: Copaxone 40 mg 3TW, daclizumab, laquinimod, ocrelizumab, Plegridy

Related 2013 Reports:

- TreatmentTrends®: Multiple Sclerosis (US)

- LaunchTrends®: Aubagio

- LaunchTrends®: Lemtrada

- LaunchTrends®: Tecfidera

- DecisionBase®: Multiple Sclerosis - Chronic Progressive

- DecisionBase®: Multiple Sclerosis - Relapsing Remitting

- PatientBase®: Multiple Sclerosis in Mexico

- PatientBase®: Multiple Sclerosis in Turkey